DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20164062

Role of staging laparoscopy to evaluate feasibility of performing optimal cytoreductive surgery in epithelial ovarian cancers

Sathyanarayanan M. Shivkumaran, Ganesh S. Mandakulutur, Keerthi R. Banavara

Abstract


Background: The main stay of treatment for epithelial ovarian cancers is surgical cytoreduction. CT scan and staging laparotomy are methods used to assess feasibility to carry out optimal cytoreduction. We evaluated the role of staging laparoscopy in assessing operability for optimal cytoreduction as well as avoidance of unnecessary laparotomies.

Methods: Between September 2014-2016, 23 patients of epithelial ovarian cancer underwent staging laparoscopy as part of evaluation method to check feasibility to carry out optimal cytoreductive surgery. The findings were correlated with clinical findings as well as CT scan findings. The impact of laparoscopy to predict operability was studied as well as its use to avoid unnecessary laparotomies.

Results: Laparoscopy could correctly evaluate the nature of abdominal mass in 91.3% patients. It picked up omental and peritoneal deposits in 87% and 95.7% patients respectively as compared to 60.9% and 39% picked up on CT scan. More importantly laparoscopy could diagnose mesenteric and small bowel deposits in 34.8% of patients which were never reported on CT scan. The overall impact was reduction in unnecessary laparotomies.

Conclusions: Laparoscopic evaluation is a useful adjunct prior to performing a formal laparotomy in epithelial ovarian cancer cytoreductive surgery.


Keywords


CT scan, Cytoreductive surgery, Ovarian cancer, Staging laparoscopy

Full Text:

PDF

References


Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;8:CD007565.

Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer. 2010;46:102-9.

Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.

Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.

Fagotti A, Fanfani F, Ludovisi M, Lo VR, Bifulco G, Testa AC, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol. 2005;96:729-35.

Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006;13:1156-61.

Brun JL, Rouzier R, Uzan S, Darai E. External validation of a laparoscopic based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol. 2008;110:354-9.

Manolitsas TP, Fowler JM. Role of laparoscopic in the management of adnexal mass and staging of gynecologic cancers. Clin ObstetGynecol 2001;44:495-521.

Canis M, Rabischong B, Houlle C, Botchorishvili R, Jardon K, Safi A, et al. Laparoscopic management of adnexal masses: a gold standard? Curr Opin Obstet Gynecol. 2002;14:423-8.

Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71:431-6.

Canis M, Rabischong B, Botchorishvili R, Tamburro S, Wattiez A, Mage G, et al. Risk of spread of ovarian cancer after laparoscopic surgery. Curr Opin Obstet Gynecol. 2001;13:9-14.

Wexner SD, Cohen SM. Port site metastases after laparoscopic colorectal surgery for cure of malignancy. Br J Surg. 1995;82:295-8.